Purple Biotech (PPBT) Competitors $2.45 +0.08 (+3.38%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. IMNN, NERV, BCTX, BGXX, CLRB, AFMD, ABP, LSB, TLPH, and PHXMShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Imunon (IMNN), Minerva Neurosciences (NERV), BriaCell Therapeutics (BCTX), Bright Green (BGXX), Cellectar Biosciences (CLRB), Affimed (AFMD), Abpro (ABP), Lakeshore Biopharma (LSB), Talphera (TLPH), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Imunon Minerva Neurosciences BriaCell Therapeutics Bright Green Cellectar Biosciences Affimed Abpro Lakeshore Biopharma Talphera PHAXIAM Therapeutics Imunon (NASDAQ:IMNN) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability. Is IMNN or PPBT more profitable? Purple Biotech's return on equity of -55.86% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -230.05% -128.98% Purple Biotech N/A -55.86%-44.67% Which has more risk & volatility, IMNN or PPBT? Imunon has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Which has higher earnings and valuation, IMNN or PPBT? Imunon has higher revenue and earnings than Purple Biotech. Purple Biotech is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K14.74-$19.51M-$1.36-0.31Purple BiotechN/AN/A-$19.88M-$5.25-0.47 Does the MarketBeat Community believe in IMNN or PPBT? Imunon received 8 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 92.59% of users gave Imunon an outperform vote. CompanyUnderperformOutperformImunonOutperform Votes2592.59% Underperform Votes27.41%Purple BiotechOutperform Votes1794.44% Underperform Votes15.56% Do analysts recommend IMNN or PPBT? Imunon presently has a consensus price target of $15.50, indicating a potential upside of 3,590.48%. Purple Biotech has a consensus price target of $33.00, indicating a potential upside of 1,246.94%. Given Imunon's higher possible upside, analysts plainly believe Imunon is more favorable than Purple Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor IMNN or PPBT? In the previous week, Imunon had 10 more articles in the media than Purple Biotech. MarketBeat recorded 13 mentions for Imunon and 3 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.54 beat Imunon's score of 0.31 indicating that Purple Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of IMNN or PPBT? 4.5% of Imunon shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 5.0% of Imunon shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryImunon beats Purple Biotech on 10 of the 16 factors compared between the two stocks. Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.26M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.289.1226.8519.75Price / SalesN/A256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book0.096.436.764.50Net Income-$19.88M$144.21M$3.23B$248.32M7 Day Performance6.75%2.25%1.71%0.48%1 Month Performance-14.93%4.39%11.16%13.08%1 Year PerformanceN/A-2.71%17.17%7.36% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech2.0472 of 5 stars$2.45+3.4%$33.00+1,246.9%N/A$3.26MN/A-0.2820News CoverageEarnings ReportGap UpIMNNImunon1.5756 of 5 stars$0.82+2.0%$21.50+2,535.1%-72.3%$11.93M$500,000.00-0.4330News CoverageAnalyst ForecastGap UpNERVMinerva Neurosciences2.9324 of 5 stars$1.66+2.9%$5.00+201.9%-41.1%$11.58MN/A-3.769News CoverageAnalyst ForecastGap UpBCTXBriaCell Therapeutics1.3105 of 5 stars$3.12+0.3%$32.00+925.6%-84.5%$11.57MN/A-0.238BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002News CoverageGap DownCLRBCellectar Biosciences2.3061 of 5 stars$0.26+6.8%$12.50+4,633.1%-92.3%$11.40MN/A-0.1510Analyst ForecastAFMDAffimed4.3862 of 5 stars$0.69+1.2%$13.50+1,848.1%-96.5%$11.16M$877,000.000.00200Analyst ForecastAnalyst RevisionABPAbproN/A$0.21+4.9%$4.00+1,806.6%N/A$10.96M$183,000.000.0015Earnings ReportGap DownHigh Trading VolumeLSBLakeshore Biopharma0.7068 of 5 stars$1.16+1.8%N/AN/A$10.80M$672.27M0.00773Positive NewsGap UpHigh Trading VolumeTLPHTalphera2.8182 of 5 stars$0.52-3.4%$5.00+858.8%-51.8%$10.69M$281,000.00-0.7619Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049 Related Companies and Tools Related Companies Imunon Competitors Minerva Neurosciences Competitors BriaCell Therapeutics Competitors Bright Green Competitors Cellectar Biosciences Competitors Affimed Competitors Abpro Competitors Lakeshore Biopharma Competitors Talphera Competitors PHAXIAM Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PPBT Stock Free PPBT Stock Alerts